| Patient selector |
|
Where there is only one approved kinase inhibitor on the market for a specific type of cancer, the patient selector application of the Matching Medicines technology could provide additional data to create the best plan for a particular patient, guiding the selection based on whether the patient is likely to respond to that drug, prior to administration. PamGene’s patient selector could help prevent non-responders having to needlessly undergo treatment with a specific drug, thereby avoiding unnecessary side effects and lost time. Research to date in breast (Lapatinib®) and lung cancer (Tarceva®) is extensive and ongoing in pursuit of validating the patient selector application.
PamGene has been working with several research groups. Retrospectively it was shown that lung cancer biopsies from different subclasses of patients have differential kinase activities. Those activities could be detected by spiking in kinase inhibitors and assessed through our Matching Medicines technology. Collaborative work in breast cancer tumors has been undertaken in conjunction with Erasmus University and the Dutch Cancer Institute in The Netherlands and the Dana Farber Cancer Institute in Boston. Numerous additional breast cancer studies involving clinical studies and cell lines are planned or have already started with Belgian, French, German and North-American cancer centers. |